Spotlight On: Enbrel® (Etanercept) / Erelzi® (Etanercept-Szzs) / Eticovo® (Etanercept-Ykro) - April 2026

Why It Matters

Understanding claim‑counting rules helps patent owners gauge litigation risk and informs strategic decisions on defending or licensing etanercept assets, a cornerstone of the biologics market.

Key Takeaways

• Claims counted separately in each litigation and IPR
• Duplicate claims may be tallied multiple times across cases
• Within a single litigation, each claim counted only once
• IPR counts treat §102 and §103 challenges as one claim

Pulse Analysis

Etanercept, the active ingredient behind blockbuster drugs Enbrel®, Erelzi® and Eticovo®, remains a pivotal asset in the global biologics market, generating billions in annual revenue. As patent portfolios age, rights holders increasingly confront challenges from competitors seeking to carve out market space. The latest legal update underscores how the United States Patent and Trademark Office (USPTO) and federal courts handle claim enumeration, a detail that can dramatically affect the perceived strength of a patent estate.

In inter partes reviews (IPRs) and infringement lawsuits, each asserted claim is recorded once per proceeding, but the same claim may be listed across multiple cases, leading to an inflated aggregate claim count. This counting method matters because it influences settlement calculations, damage assessments, and the allocation of legal resources. Moreover, the USPTO treats §102 novelty and §103 non‑obviousness challenges as a single claim within an IPR, simplifying docket management but potentially obscuring the nuance of each argument.

For biotech firms and their legal teams, the practical takeaway is to monitor not just the number of claims but the overlap across forums. Duplicate counting can exaggerate exposure, prompting more aggressive licensing or defensive filing strategies. Conversely, understanding the single‑claim treatment in IPRs can streamline defense planning and budget forecasting. As the industry navigates an increasingly litigious patent landscape, precise claim accounting becomes a strategic lever for protecting high‑value therapeutics like etanercept.